Abstract
PURPOSE: To evaluate the efficacy and tolerability of pioglitazone in combination with a sulfonylurea in the treatment of type 2 diabetes mellitus. SUBJECTS AND METHODS: This 16-week, double-blind study included patients on a stable regimen of a sulfonylurea for ≥30 days and with a glycosylated hemoglobin (HbA1C) level ≥8.0%. Patients were randomly assigned to receive once daily pioglitazone 15 mg (n = 184), pioglitazone 30 mg (n = 189), or placebo plus sulfonylurea (n = 187). RESULTS: Patients receiving pioglitazone + sulfonylurea had significant (P 1C and fasting plasma glucose levels compared with patients treated with placebo + sulfonylurea. As compared with placebo, HbA1C decreased by 0.9% (95% confidence interval [CI]: 0.06% to 1.2%) with pioglitazone 15 mg and 1.3% (CI: 1% to 1.6%) with 30 mg pioglitazone; fasting plasma glucose levels decreased by 39 mg/dL (95% CI: 27 to 52 mg/dL) with pioglitazone 15 mg and by 58 mg/dL (95% CI: 46-70 mg/dL) with 30 mg pioglitazone. Both pioglitazone + sulfonylurea groups had significant (P 1C and fasting plasma glucose levels with beneficial effects on serum triglyceride and HDL-cholesterol levels.
| Original language | English |
|---|---|
| Pages (from-to) | 10-17 |
| Number of pages | 8 |
| Journal | American Journal of Medicine |
| Volume | 111 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2001 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Nursing(all)
Cite this
Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus : A randomized, placebo-controlled study. / Kipnes, Mark S.; Krosnick, Arthur; Rendell, Marc S.; Egan, John W.; Mathisen, Annette L.; Schneider, Roberta L.
In: American Journal of Medicine, Vol. 111, No. 1, 2001, p. 10-17.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus
T2 - A randomized, placebo-controlled study
AU - Kipnes, Mark S.
AU - Krosnick, Arthur
AU - Rendell, Marc S.
AU - Egan, John W.
AU - Mathisen, Annette L.
AU - Schneider, Roberta L.
PY - 2001
Y1 - 2001
N2 - PURPOSE: To evaluate the efficacy and tolerability of pioglitazone in combination with a sulfonylurea in the treatment of type 2 diabetes mellitus. SUBJECTS AND METHODS: This 16-week, double-blind study included patients on a stable regimen of a sulfonylurea for ≥30 days and with a glycosylated hemoglobin (HbA1C) level ≥8.0%. Patients were randomly assigned to receive once daily pioglitazone 15 mg (n = 184), pioglitazone 30 mg (n = 189), or placebo plus sulfonylurea (n = 187). RESULTS: Patients receiving pioglitazone + sulfonylurea had significant (P 1C and fasting plasma glucose levels compared with patients treated with placebo + sulfonylurea. As compared with placebo, HbA1C decreased by 0.9% (95% confidence interval [CI]: 0.06% to 1.2%) with pioglitazone 15 mg and 1.3% (CI: 1% to 1.6%) with 30 mg pioglitazone; fasting plasma glucose levels decreased by 39 mg/dL (95% CI: 27 to 52 mg/dL) with pioglitazone 15 mg and by 58 mg/dL (95% CI: 46-70 mg/dL) with 30 mg pioglitazone. Both pioglitazone + sulfonylurea groups had significant (P 1C and fasting plasma glucose levels with beneficial effects on serum triglyceride and HDL-cholesterol levels.
AB - PURPOSE: To evaluate the efficacy and tolerability of pioglitazone in combination with a sulfonylurea in the treatment of type 2 diabetes mellitus. SUBJECTS AND METHODS: This 16-week, double-blind study included patients on a stable regimen of a sulfonylurea for ≥30 days and with a glycosylated hemoglobin (HbA1C) level ≥8.0%. Patients were randomly assigned to receive once daily pioglitazone 15 mg (n = 184), pioglitazone 30 mg (n = 189), or placebo plus sulfonylurea (n = 187). RESULTS: Patients receiving pioglitazone + sulfonylurea had significant (P 1C and fasting plasma glucose levels compared with patients treated with placebo + sulfonylurea. As compared with placebo, HbA1C decreased by 0.9% (95% confidence interval [CI]: 0.06% to 1.2%) with pioglitazone 15 mg and 1.3% (CI: 1% to 1.6%) with 30 mg pioglitazone; fasting plasma glucose levels decreased by 39 mg/dL (95% CI: 27 to 52 mg/dL) with pioglitazone 15 mg and by 58 mg/dL (95% CI: 46-70 mg/dL) with 30 mg pioglitazone. Both pioglitazone + sulfonylurea groups had significant (P 1C and fasting plasma glucose levels with beneficial effects on serum triglyceride and HDL-cholesterol levels.
UR - http://www.scopus.com/inward/record.url?scp=0034933056&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034933056&partnerID=8YFLogxK
U2 - 10.1016/S0002-9343(01)00713-6
DO - 10.1016/S0002-9343(01)00713-6
M3 - Article
VL - 111
SP - 10
EP - 17
JO - American Journal of Medicine
JF - American Journal of Medicine
SN - 0002-9343
IS - 1
ER -